Today: 1 May 2026
Browse Category

NASDAQ:QNRX 11 October 2025 - 11 November 2025

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals announced it achieved 4% rapamycin in a topical lotion and 5% in a dermal patch, clearing a key formulation barrier for human trials. QNRX shares surged, with pre-market gains near 66%. Clinical and stability batch manufacturing is set for late 2025, with first-in-human studies planned for early 2026 targeting microcystic lymphatic and venous malformations.
11 November 2025
···
Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharma (QNRX) Stock Skyrockets 150% on Funding Deal – What’s Next?

Quoin Pharmaceuticals shares surged over 150% on Oct. 10, closing at $20.50 after announcing a $104.5 million private placement with institutional healthcare investors. Intraday, the stock touched $41.80 before retreating. Market cap rose to about $160–170 million. The company, which has no products on the market, is developing QRX003 for Netherton Syndrome and recently secured FDA and EMA orphan drug designations.
11 October 2025
·

Stock Market Today

  • Xpedra Resources Seeks ASX Quotation for 93.9 Million New Shares
    April 30, 2026, 10:30 PM EDT. Xpedra Resources Limited has applied for quotation of 93,888,000 new ordinary shares on the Australian Securities Exchange under ticker XPD. Issued on April 30, 2026, these shares expand the company's capital base, potentially enhancing liquidity and supporting future funding. This move could alter shareholder structure and trading patterns, broadening the investor base and increasing market visibility. Xpedra, an Australian mineral exploration company, emphasizes capital market activity over operational updates in this filing. With a current market cap of A$13.83 million and average trading volume near 2 million shares, the development signals continued reliance on equity to advance strategic objectives in the resources sector.

Latest article

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

Nvidia Stock Falls as Google and Amazon AI Chip Push Tests the AI Trade

30 April 2026
Nvidia shares dropped 4.6% to $199.57 Thursday as investors reacted to Alphabet and Amazon expanding sales of their own AI chips. Alphabet reported Google Cloud revenue up 63% and began selling TPU chips directly to customers. AMD and Broadcom shares rose 5.1% and 3.0%, respectively. Amazon said its Trainium chip line secured $225 billion in revenue commitments.
Go toTop